Medical Condition News

RSS

Ipsen, Inspiration partner to commercialize IB1001 and OBI-1 for hemophilia

Inspiration Biopharmaceuticals Inc. today announced new license, development and commercialization agreements with its strategic partner, Ipsen.

21 Aug 2012

Pregnant women have higher rate of undiagnosed depression

Major depression affects as many as 16% of reproductive-aged women in the U.S. Yet pregnant women have a higher rate of undiagnosed depression than nonpregnant women, according to a study published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

21 Aug 2012

India's CNBC-TV18 examines implications of country's decision to issue compulsory license for Bayer cancer drug

"India's grant of a compulsory license to Natco for Bayer's kidney-cancer drug Nexavar has sent shockwaves across the globe," but "India has found a backer in the World Health Organization," CNBC-TV18's "moneycontrol.com" reports.

21 Aug 2012

Study finds decline in incidence of heart failure cases in Ontario

The number of new cases of heart failure in Ontario decreased 33% over a decade, suggesting preventive efforts may be working. However, mortality rates remain high for people with the disease, states a study published in CMAJ (Canadian Medical Association Journal).

21 Aug 2012

Thiabendazole drug slows tumor growth and shows promise as chemotherapy for cancer

An inexpensive antifungal drug, thiabendazole, slows tumor growth and shows promise as a chemotherapy for cancer. Scientists in the College of Natural Sciences at The University of Texas at Austin made this discovery by exploiting the evolutionary relatedness of yeast, frogs, mice and humans.

21 Aug 2012

Studies raise possibility of new DBS approaches to treat obesity

Scientific advances in understanding the "addiction circuitry" of the brain may lead to effective treatment for obesity using deep brain stimulation (DBS), according to a review article in the August issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

21 Aug 2012

New neurotechnology aims to help rehabilitate stroke survivors

What comes naturally to most people - to think and then do - is difficult for stroke patients who have lost the full use of their limbs. New research by Rice University, the University of Houston (UH) and TIRR Memorial Hermann aims to help victims recover that ability to the fullest extent possible with a $1.17 million grant from the National Institutes of Health (NIH) and the President's National Robotics Initiative (NRI).

21 Aug 2012

Acupuncture could save treatment costs and offer viable alternative to knee replacement surgery

The researchers base their findings on 90 patients with knee osteoarthritis, who were referred for group acupuncture to two knee pain clinics in St Albans, Hertfordshire, in 2008 and subsequently monitored for two years.

21 Aug 2012

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.

21 Aug 2012

Controversial activities of pro-anorexic bloggers may have benefits

A groundbreaking new research study from Indiana University suggests there may be benefits to the controversial activities of "pro-ana" bloggers, the online community for people with eating disorders.

20 Aug 2012

Injectable controlled-release capsules against gum disease

Scientists are trying to open a new front in the battle against gum disease, the leading cause of tooth loss in adults and sometimes termed the most serious oral health problem of the 21st century. They described another treatment approach for the condition in a report here today at the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society.

20 Aug 2012

PPR proteins recognise RNA targets via easy-to-understand code

The code determines the recognition of RNA molecules by a superfamily of RNA-binding proteins called pentatricopeptide repeat (PPR) proteins.

20 Aug 2012

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company's investigational BCR-ABL inhibitor.

20 Aug 2012

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012

Enrollment complete in BDSI's pivotal pharmacokinetic study of BNX for opioid dependence

BioDelivery Sciences International, Inc. announced that enrollment and the clinical portion of the pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence has been completed.

20 Aug 2012

FDA approves InSightec's ExAblate Neuro system clinical trial for tremor dominant Parkinson's Disease

InSightec Ltd, the global leader in MR guided Focused Ultrasound (MRgFUS), announced that it has received approval from the US Food and Drug Administration to begin a Phase I clinical trial evaluating the use of its ExAblate Neuro system for the treatment of patients with tremor dominant Parkinson's Disease.

20 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Protein toxic to nerve cells in AD also contributes to memory loss

The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease patients have elevated levels of BACE1, which in turn leads to more brain-damaging β-amyloid protein.

20 Aug 2012

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

Abbott today announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease.

20 Aug 2012

Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd

Cervical Cancer is a tragic disease. First and foremost, because it is entirely preventable if the early symptoms are detected in a timely manner

20 Aug 2012

Medical Condition News

Ipsen, Inspiration partner to commercialize IB1001 and OBI-1 for hemophilia

Pregnant women have higher rate of undiagnosed depression

India's CNBC-TV18 examines implications of country's decision to issue compulsory license for Bayer cancer drug

Study finds decline in incidence of heart failure cases in Ontario

Thiabendazole drug slows tumor growth and shows promise as chemotherapy for cancer

Studies raise possibility of new DBS approaches to treat obesity

New neurotechnology aims to help rehabilitate stroke survivors

Acupuncture could save treatment costs and offer viable alternative to knee replacement surgery

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Controversial activities of pro-anorexic bloggers may have benefits

Injectable controlled-release capsules against gum disease

PPR proteins recognise RNA targets via easy-to-understand code

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Enrollment complete in BDSI's pivotal pharmacokinetic study of BNX for opioid dependence

FDA approves InSightec's ExAblate Neuro system clinical trial for tremor dominant Parkinson's Disease

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Protein toxic to nerve cells in AD also contributes to memory loss

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News